Regulatory status by jurisdiction (revision 7)
Old revision·11:20, 8 Jan 2025·UACR_Ulric
| Regulatory status by jurisdiction | |
|---|---|
| Determined by | Regulatory category, not chemical identity |
| Categories | Medicine, research reagent, controlled substance, unregulated |
| Consequence | The same molecule differs in status between countries |
| Topic infobox · conventions | |
Regulatory status by jurisdiction describes how the legal treatment of a substance differs between countries. Status follows from the regulatory category a substance occupies in a given jurisdiction, and the same molecule may be a licensed medicine in one, an unapproved investigational compound in another, and a research reagent in a third.[1]
Category is not a property of the chemistry. It follows from whether a marketing authorisation exists, what the substance is presented for, and whether it appears on any scheduling list.[2]
This article describes the structure of the question. It does not state the law of any jurisdiction, does not advise on legality, and should not be relied on for either.[3]
The categories
[edit]| Category | Typical consequence |
|---|---|
| Authorised medicine | Prescription and distribution rules apply |
| Unapproved investigational compound | Not lawfully supplied as a medicine |
| Research reagent | Supplied for laboratory use; not for administration |
| Controlled substance | Scheduling rules; possession may be an offence |
| Unregulated | Ordinary commercial law only |
Most peptides discussed on this wiki sit in the second or third category in most jurisdictions. The Research use only designation is a statement of the third and is a presentation as much as a status: the same material presented as a medicine is a medicine.[4]
The presentation test is the mechanism by which many jurisdictions treat a product: claims made about a substance can bring it within medicines law regardless of what the label says elsewhere.[2]
References
- ^ World Customs Organization, International Convention on the Simplification and Harmonization of Customs Procedures (revised Kyoto Convention).
- ^ a b United States Food and Drug Administration, Regulatory Procedures Manual, chapter 9 (coverage of personal importations).
- ^ International Council for Harmonisation, Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients (2000).
- ^ United States Pharmacopeia, General Chapter <1503>, Quality Attributes of Synthetic Peptide Drug Substances.